Funders › MA › Alzheimer's Disease Research Foundation › 2021
Grants paid by Alzheimer's Disease Research Foundation, tax year 2021
EIN 52-2396428 · Wellesley Hls, MA · Form 990, Schedule I · NTEE H83
In tax year 2021, Alzheimer's Disease Research Foundation (EIN 52-2396428) reported 76 grants paid totaling $15,183,443. Dataset version 2026.09.0, built 2026-09-03.
Every grant, 2021
| Tax year | Recipient | Match | Amount | Type | Purpose | Source filing |
|---|---|---|---|---|---|---|
| 2021 | Massachusetts General Hospital Boston, MA | A | $1,495,000 | paid | THE CURE ALZ ALZHEIMER'S GENOME PROJECT | 202241309349304019 |
| 2021 | The Broad Institute Inc Cambridge, MA | A | $550,000 | paid | CIRCUITS: CONSORTIUM TO INFER REGULATORY CIRCUITS AND UNCOVER INNOVATIVE THERAPEUTIC STRATEGIES PRODUCTION GROUP | 202241309349304019 |
| 2021 | Whitehead Institute for Biomedical Research Cambridge, MA | A | $307,500 | paid | CIRCUITS: IMPACT OF GENETIC, EPIGENETIC AND CELLULAR VARIANTS ON ALZHEIMER'S DISEASE PATHOLOGY | 202241309349304019 |
| 2021 | Massachusetts General Hospital Boston, MA | A | $300,000 | paid | UNDERSTANDING HUMAN BRAIN RESILIENCE TO ALZHEIMER'S PATHOLOGY | 202241309349304019 |
| 2021 | Washington University St Louis St Louis, MO | A | $300,000 | paid | APOE CONSORTIUM: UNDERSTANDING THE EFFECT OF APOE ON TAU-MEDIATED NEURODEGENERATION | 202241309349304019 |
| 2021 | The University of California San Diego La Jolla, CA | A | $291,374 | paid | CONTINUING STUDIES OF THE EFFECTS OF GSM 776890 ADMINISTRATION ON AMYLOID SPECIES AND MICROGLIOSIS IN OLDER ALZHEIMER'S MODEL MICE | 202241309349304019 |
| 2021 | University of Southern California Los Angeles, CA | A | $257,679 | paid | AIR POLLUTION AND AD RISK INTERACT WITH PREMATURE AGING OF NEURAL STEM CELLS AND APOE ALLELES | 202241309349304019 |
| 2021 | Washington University St Louis St Louis, MO | A | $250,000 | paid | BRAIN ENTRY & EXIT CONSORTIUM: CROSSTALK OF CNS BARRIERS AND CLEARANCE ROUTES IN HOMEOSTASIS AND ALZHEIMER'S DISEASE | 202241309349304019 |
| 2021 | Mayo Clinic Rochester, MN | A | $250,000 | paid | APOE CONSORTIUM: COUNTERACTING PATHOGENIC EVENTS IN AD WITH PERIPHERAL OR CENTRAL APOE | 202241309349304019 |
| 2021 | Massachusetts General Hospital Boston, MA | A | $250,000 | paid | CHARACTERIZING GUT MICROBIOME SYNERGY WITH EMPHASIS ON MYCOBIOME AND ITS IMPACT ON ALZHEIMER'S DISEASE (AD) PATHOLOGY IN AD MOUSE MODELS | 202241309349304019 |
| 2021 | Brigham and Women's Hospital Boston, MA | A | $250,000 | paid | APOE CONSORTIUM: THE ROLE OF APOE IN MICROGLIA REGULATION IN NEURODEGENERATION | 202241309349304019 |
| 2021 | Weill Medical College of Cornell University New York, NY | A | $250,000 | paid | DEVELOPMENT OF HUMAN CGAS INHIBITORS TO TREAT ALZHEIMER'S DISEASE | 202241309349304019 |
| 2021 | The Trustees of Boston University Boston, MA | A | $250,000 | paid | APOE CONSORTIUM: REGULATION BY APOE OF SELECTIVE NEURONAL VULNERABILITY TO ALZHEIMER'S DISEASE | 202241309349304019 |
| 2021 | University of Texas Southwestern Medical Center Dallas, TX | A | $250,000 | paid | MECHANISMS OF TAU PROPAGATION ACROSS THE PLASMA MEMBRANE | 202241309349304019 |
| 2021 | New York University School of Medicine New York, NY | A | $250,000 | paid | NEUROINFLAMMATION CONSORTIUM: INVESTIGATION OF AD RISK ALLELES IN ASTROCYTES FOCUS ON CHOLESTEROL TRANSPORT AND MICROGLIA INTERACTION | 202241309349304019 |
| 2021 | University of Southern California Los Angeles, CA | A | $250,000 | paid | CELLULAR AND MOLECULAR STUDIES OF APOE REGULATION OF BLOOD-BRAIN BARRIER, SYNAPTIC AND NEURONAL FUNCTIONS AND PROTECTION STRATEGIES IN MOUSE MODELS WITH AND WITHOUT ALZHEIMER'S PATHOLOGY | 202241309349304019 |
| 2021 | Beth Israel Deaconess Medical Center Boston, MA | A | $249,026 | paid | CIRCUITS: A UNIFIED APPROACH TO ACTIONABLE ALZHEIMER'S DISEASE SIGNATURES | 202241309349304019 |
| 2021 | Harvard College Boston, MA | A | $244,496 | paid | ANALYTICAL AND STATISTICAL TOOLS FOR SEQUENCE ANALYSIS FOR ALZHEIMER'S DISEASE | 202241309349304019 |
| 2021 | University of Virginia Charlottesville, VA | A | $229,249 | paid | ADULT HUMAN INEURONS: A NEXT GENERATION DRUG SCREENING PLATFORM FOR ALZHEIMER'S DISEASE | 202241309349304019 |
| 2021 | Houston Methodist Hospital Foundation Houston, TX | A | $200,000 | paid | 3DDS CONSORTIUM: UNCOVERING THE MOLECULAR MECHANISMS OF SELECTED DRUG CANDIDATES DERIVED FROM SYSTEMATIC ALZHEIMER'S DRUG REPOSITIONING | 202241309349304019 |
| 2021 | Carnegie Mellon University Pittsburgh, PA | A | $200,000 | paid | CIRCUITS: INTERPRETING ALZHEIMER'S DISEASEASSOCIATED GENETIC VARIATION AT ENHANCER REGIONS | 202241309349304019 |
| 2021 | University of Southern California Los Angeles, CA | A | $191,008 | paid | PROTECTION AGAINST APOE4 WITH LONGEVITY-PROMOTING INTERVENTIONS | 202241309349304019 |
| 2021 | Brigham and Women's Hospital Boston, MA | A | $178,612 | paid | IMMUNOTHERAPIES TARGETING THE MICROBIOTA TO PREVENT COGNITIVE DECLINE IN ALZHEIMER'S DISEASE | 202241309349304019 |
| 2021 | New York University School of Medicine New York, NY | A | $174,754 | paid | THE ROLE OF ASTROCYTE-DERIVED TOXIC LIPIDS MEDIATING DEGENERATION IN AD | 202241309349304019 |
| 2021 | Mayo Clinic Rochester, MN | A | $172,500 | paid | HARNESSING MENINGEAL LYMPHATICS AND IMMUNITY TO ALLEVIATE APOE4-INDUCED BRAIN DYSFUNCTION | 202241309349304019 |
| 2021 | The University of California San Diego La Jolla, CA | A | $172,500 | paid | BRAIN ENTRY & EXIT CONSORTIUM: IDENTIFYING THE BLOOD-BRAIN BARRIER CHANGES DURING ALZHEIMER'S DISEASE | 202241309349304019 |
| 2021 | Massachusetts General Hospital Boston, MA | A | $172,500 | paid | EFFECTS OF DE-PALMITOYLATION AND ACAT INHIBITION ON AXONAL AB GENERATION VIA MAM-ASSOCIATED PALAPP | 202241309349304019 |
| 2021 | The University of California San Diego La Jolla, CA | A | $172,500 | paid | FUNCTIONAL BASIS FOR NOVEL PKC, K56R MUTATION IN ALZHEIMER'S DISEASE | 202241309349304019 |
| 2021 | Massachusetts General Hospital Boston, MA | A | $172,500 | paid | ALZHEIMER'S DISEASE DRUG DISCOVERY AND DEVELOPMENT CONSORTIUM: MODULATING CD33 FUNCTION AND NEUROINFLAMMATION AS A THERAPEUTIC APPROACH FOR ALZHEIMER'S DISEASE | 202241309349304019 |
| 2021 | Massachusetts General Hospital Boston, MA | A | $172,500 | paid | NEUROPROTECTIVE EFFECTS OF THE EXERCISE HORMONE IRISIN IN ALZHEIMER'S DISEASE | 202241309349304019 |
| 2021 | Washington University St Louis St Louis, MO | A | $172,500 | paid | CONTRIBUTION OF SKULL BONE MARROW-DERIVED CELLS TO ALZHEIMER'S DISEASE | 202241309349304019 |
| 2021 | Massachusetts General Hospital Boston, MA | A | $172,500 | paid | DEVELOPMENT OF A MULTICELLULAR BRAIN MODEL TO STUDY BRAIN-VASCULAR-PERIPHERAL IMMUNE CELLS CROSSTALK IN ALZHEIMER'S DISEASE | 202241309349304019 |
| 2021 | Washington University St Louis St Louis, MO | A | $172,500 | paid | UNDERSTANDING THE ROLE OF NATURAL AB-SPECIFIC B CELL RESPONSES IN AD PROGRESSION | 202241309349304019 |
| 2021 | Icahn School of Medicine at Mount Sinai New York, NY | A | $172,500 | paid | ESTABLISHING THE MOLECULAR AND CELLULAR MECHANISMS AND BIOMARKERS OF APOE4-MEDIATED SUSCEPTIBILITY TO TAU-RELATED COGNITIVE IMPAIRMENTS | 202241309349304019 |
| 2021 | Memorial Sloan Kettering Cancer New York, NY | A | $172,500 | paid | THE ROLE OF IFITM3 AND GAMMA SECRETASE IN MICROGLIA | 202241309349304019 |
| 2021 | Massachusetts General Hospital Boston, MA | A | $172,500 | paid | TAU AND B-AMYLOID ARE INNATE IMMUNE ANTIMICROBIAL | 202241309349304019 |
| 2021 | Washington University St Louis St Louis, MO | A | $172,500 | paid | NEURONAL SUBTYPE-SPECIFIC MODELING OF ALZHEIMER'S DISEASE BY DIRECT NEURONAL REPROGRAMMING OF PATIENT FIBROBLASTS | 202241309349304019 |
| 2021 | Mayo Clinic Rochester, MN | A | $172,500 | paid | THE ROLE OF CLUSTERIN IN TAU PATHOLOGY | 202241309349304019 |
| 2021 | The Trustees of Boston University Boston, MA | A | $172,500 | paid | ALZHEIMER'S DISEASE DRUG DISCOVERY AND DEVELOPMENT CONSORTIUM: BLOCKING SYNAPTOTOXICITY IN ALZHEIMER'S 3D MODELS | 202241309349304019 |
| 2021 | The University of California San Diego La Jolla, CA | A | $172,500 | paid | THE NEDD4-1 AND PKCA CONNECTION IN ALZHEIMER'S DISEASE | 202241309349304019 |
| 2021 | Mayo Clinic Jacksonville Jacksonville, FL | A | $172,500 | paid | ABCA7 LOSS OF FUNCTION IN AGING AND ALZHEIMER'S DISEASE | 202241309349304019 |
| 2021 | Brigham and Women's Hospital Boston, MA | A | $172,500 | paid | ROLE OF CHECKPOINT MOLECULE TIM-3 IN REGULATING MICROGLIA IN ALZHEIMER'S DISEASE | 202241309349304019 |
| 2021 | The Salk Institute for Biological Studies La Jolla, CA | A | $172,500 | paid | THE ROLE OF ASTROCYTE-SECRETED IGFBP2 IN THE PROGRESSION OF ALZHEIMER'S DISEASE | 202241309349304019 |
| 2021 | The Rockefeller University New York, NY | A | $172,500 | paid | APOE CONSORTIUM: REGULATION BY APOE OF SELECTIVE NEURONAL VULNERABILITY TO ALZHEIMER'S DISEASE (YEAR 3) | 202241309349304019 |
| 2021 | University of Southern California Los Angeles, CA | A | $172,500 | paid | AIR POLLUTION AND AD RISK INTERACT WITH PREMATURE AGING OF NEURAL STEM CELLS AND APOE ALLELES | 202241309349304019 |
| 2021 | Yale University New Haven, CT | A | $172,500 | paid | THE NEUROPROTECTIVE GLIAL BARRIER: A MULTICELLULAR REACTION WITH THERAPEUTIC POTENTIAL IN AD | 202241309349304019 |
| 2021 | Mayo Clinic Rochester, MN | A | $172,500 | paid | PATIENT-BASED STRUCTURAL AND FUNCTIONAL BIOLOGY OF TAUOPATHIES (YEAR 2) | 202241309349304019 |
| 2021 | Massachusetts General Hospital Boston, MA | A | $172,500 | paid | ALZHEIMER'S DISEASE DRUG DISCOVERY AND DEVELOPMENT CONSORTIUM: HIGH-THROUGHPUT DRUG SCREENING FOR ALZHEIMER'S DISEASE USING 3D HUMANNEURAL CULTURE SYSTEMS YR 1 OF 2 | 202241309349304019 |
| 2021 | Massachusetts General Hospital Boston, MA | A | $172,500 | paid | NEUROPROTECTIVE EFFECTS OF THE EXERCISE HORMONE IRISIN IN ALZHEIMER'S DISEASE | 202241309349304019 |
| 2021 | University of Virginia Charlottesville, VA | A | $172,500 | paid | TARGETING A MASTER INNATE IMMUNE ADAPTOR MOLECULE IN ALZHEIMER'S DISEASE | 202241309349304019 |
| 2021 | Brigham and Women's Hospital Boston, MA | A | $172,500 | paid | THE ROLE OF MGND-NEURODEGENERATIVE CLEC7A+ MICROGLIA IN AN AD MOUSE MODEL | 202241309349304019 |
| 2021 | Icahn School of Medicine at Mount Sinai New York, NY | A | $172,500 | paid | SYSTEMS INTEGRATION AND THERAPEUTICS TRANSLATION. | 202241309349304019 |
| 2021 | Weill Medical College of Cornell University New York, NY | A | $172,500 | paid | BRAIN ENTRY AND EXIT CONSORTIUM: LYMPHATICS AND CNS FLUID HOMEOSTASIS | 202241309349304019 |
| 2021 | Mayo Clinic Jacksonville Jacksonville, FL | A | $172,500 | paid | TARGETING MICROGLIAL TSG 101 FOR SYNAPTIC PROTECTION AND COGNITIVE ENHANCEMENT IN ALZHEIMER'S DISEASE | 202241309349304019 |
| 2021 | Icahn School of Medicine at Mount Sinai New York, NY | A | $172,500 | paid | INVESTIGATING BONE MARROW HEMATOPOIESIS AS THE LINK BETWEEN SLEEP FRAGMENTATION AND VASCULAR INFLAMMATION IN AD | 202241309349304019 |
| 2021 | Weill Medical College of Cornell University New York, NY | A | $172,500 | paid | ROLE OF MICROGLIA IN DEGRADATION AND TRIMMING OF ALZHEIMER'S AMYLOID BETA | 202241309349304019 |
| 2021 | Brigham and Women's Hospital Boston, MA | A | $172,500 | paid | TARGETING THE MICROBIOME AND INNATE IMMUNITY | 202241309349304019 |
| 2021 | Massachusetts General Hospital Boston, MA | A | $172,500 | paid | G2T, AD4, ACTFAST AND GENERAL SCIENTIFIC SUPPORT | 202241309349304019 |
| 2021 | Northwestern University Evanston, IL | A | $172,500 | paid | T CELL EPIGENETICS IN ALZHEIMER'S DISEASE | 202241309349304019 |
| 2021 | Unversity of Kentucky Lexington, KY | A | $172,500 | paid | APOLIPOPROTEIN E AND IMMUNOMETABOLISM IN ALZHEIMER'S DISEASE | 202241309349304019 |
| 2021 | The Broad Institute Inc Cambridge, MA | A | $172,500 | paid | REVEALING NEW GENES AND PATHWAYS AT THE INTERSECTION OF LIPOTOXIC AND GENETIC RISK FOR ALZHEIMER'S DISEASE | 202241309349304019 |
| 2021 | Massachusetts General Hospital Boston, MA | A | $170,907 | paid | EFFECTS OF CEREBROVASCULAR INSUFFICIENCY AND EXERCISE ON THE AD BRAIN VASCULOMA | 202241309349304019 |
| 2021 | The Baylor College of Medicine Houston, TX | A | $167,920 | paid | ELUCIDATING THE ROLE OF SOLUBLE EPOXIDE HYDROLASE AND ARACHIDONIC ACID METABOLISM IN NEUROINFLAMMATION AND ALZHEIMER'S DISEASE | 202241309349304019 |
| 2021 | Northwestern University Evanston, IL | A | $164,314 | paid | INTERROGATING LEVETIRACETAM'S IMPACT ON AMYLOID PATHOLOGY AND PRESYNAPTIC PROTEOSTASIS IN KNOCK-IN MOUSE MODELS WITH HUMANIZED ABETA | 202241309349304019 |
| 2021 | Boston Childrens Hospital Boston, MA | A | $138,000 | paid | NEUROINFLAMMATION CONTRIBUTIONS TO ALZHEIMER'S DISEASE: ROLE OF THE CHOROID PLEXUS | 202241309349304019 |
| 2021 | Massachusetts General Hospital Boston, MA | A | $115,000 | paid | (YR 2) BRAIN ENTRY & EXIT CONSORTIUM: HUMAN 3D NEUROVASCULAR INTERACTION AND MENINGEAL LYMPHATICS MODELS WITH APPLICATION TO ALZHEIMER'S DISEASE | 202241309349304019 |
| 2021 | The Salk Institute for Biological Studies La Jolla, CA | A | $115,000 | paid | CIRCUITS: IMPACT OF EPIGENETIC AND CELLULAR VARIANTS ON ALZHEIMER'S DISEASE PATHOLOGY | 202241309349304019 |
| 2021 | Yale University New Haven, CT | A | $114,679 | paid | 2021 BEE: BENVENISTE TANNENBAUM: BRAIN ENTRY & EXIT CONSORTIUM: GLYMPHATIC-LYMPHATIC COUPLING IN ALZHEIMER'S DISEASE | 202241309349304019 |
| 2021 | Massachusetts Institute of Techonology Cambridge, MA | A | $100,000 | paid | (YR 2) BRAIN ENTRY & EXIT CONSORTIUM: HUMAN 3D NEUROVASCULAR INTERACTION AND MENINGEAL LYMPHATICS MODELS WITH APPLICATION TO ALZHEIMER'S DISEASE | 202241309349304019 |
| 2021 | Amylyx Cambridge, MA | A | $78,234 | paid | PEGASUS CLINICAL STUDY OF AMX0035 IN ALZHEIMER'S DISEASE | 202241309349304019 |
| 2021 | Massachusetts General Hospital Boston, MA | A | $58,090 | paid | HIGH-THROUGHPUT DRUG SCREENING FOR ALZHEIMER'S DISEASE USING 3D HUMAN | 202241309349304019 |
| 2021 | Stonybrook University Stoney Book, NY | A | $50,051 | paid | 3DDS CONSORTIUM: PROTEOMICS OF ALZHEIMER'S DISEASE 3D CULTURES | 202241309349304019 |
| 2021 | The Brain Donor Project Naples, FL | A | $35,050 | paid | TARGET RECRUITMENT OF UNDERREPRESENTED AMERICANS FOR BRAIN DONOR REGISTRATION | 202241309349304019 |
| 2021 | Houston Methodist Hospital Foundation Houston, TX | A | $25,000 | paid | SUPPLEMENT | 202241309349304019 |
| 2021 | Massachusetts General Hospital Boston, MA | A | $25,000 | paid | MODULATING CD33 FUNCTION AND NEUROINFLAMMATION AS A THERAPEUTIC APPROACH FOR AD | 202241309349304019 |
| 2021 | The Trustees of Boston University Boston, MA | A | $25,000 | paid | BLOCKING SYNAPTOTOXICITY IN ALZHEIMER'S 3D MODELS | 202241309349304019 |
Match tier: A Reported EIN · B Exact name and place · C Strong name match · D Probable name match · U Unresolved. Tiers C and D are inferred, not reported; see how matching works.
Recipient matching for this dataset version has not yet completed its independent precision check. Tier A rows carry the EIN the filer reported; tiers B–D are the matcher's inference and should be read as leads until the check is published on the methodology page.
Derived from IRS Form 990 e-file XML. Dataset version 2026.09.0, built 2026-09-03. All years for this funder.
The same organization elsewhere in the program: exempt status and filing health · federal awards · grant guidance · open opportunities.
This is informational only, derived from public data on the dates shown. It is not an eligibility determination, and not legal, tax, or accounting advice. Verify against the official source before relying on it.